
浏览全部资源
扫码关注微信
湖北医药学院附属人民医院妇产科,湖北 十堰 442000
纸质出版日期:2024-10-25,
收稿日期:2023-09-30,
移动端阅览
刘莹,范丽.卵巢癌组织长链非编码RNA PVT1表达及其靶基因生物信息学预测研究[J].局解手术学杂志,2024,33(10):871-875.
LIU Ying,FAN Li.Expression of long non-coding RNA PVT1 and bioinformatics prediction of its target gene in ovarian cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(10):871-875.
刘莹,范丽.卵巢癌组织长链非编码RNA PVT1表达及其靶基因生物信息学预测研究[J].局解手术学杂志,2024,33(10):871-875. DOI: 10.11659/jjssx.09E023132.
LIU Ying,FAN Li.Expression of long non-coding RNA PVT1 and bioinformatics prediction of its target gene in ovarian cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(10):871-875. DOI: 10.11659/jjssx.09E023132.
目的
2
检测长链非编码RNA浆细胞瘤多样异位基因1(lncRNA PVT1)在卵巢癌组织中的表达并预测其靶基因,进而对靶基因进行生物信息学分析。
方法
2
收集2019年6月至2019年12月于我院行手术治疗的125例卵巢癌患者的癌组织及其切缘正常组织。RT-PCR检测癌组织及其切缘正常组织lncRNA PVT1的表达;比较不同临床病理特征患者卵巢癌组织lncRNA PVT1表达;应用在线工具Annolnc2数据库、GEPIA2数据库、UALCAN数据库分别筛选出lncRNA PVT1靶基因取交集;采用DAVID数据库对筛选出的lncRNA PVT1靶基因进行GO功能和KEGG通路富集分析。
结果
2
与切缘正常组织相比,癌组织中lncRNA PVT1相对表达水平升高(
P
<
0.05);TNM分期Ⅲ~Ⅳ期、低/未分化程度的卵巢癌患者癌组织中lncRNA PVT1的相对表达水平分别高于TNM分期Ⅰ~Ⅱ期、中/高分化程度的卵巢癌患者(
P
<
0.05);lncRNA PVT1的靶基因有44个,GO功能分析发现靶基因功能主要富集于细胞周期调控、RNA聚合酶Ⅱ启动子的转录调控、转录因子活性、赖氨酰氧化酶活性、细胞外基质、细胞质等;KEGG通路分析显示其参与的通路主要富集于癌症相关信号通路、转化生长因子-β(TGF-β)信号通路、细胞外基质受体的相互作用、环磷酸鸟苷酸(cGMP)-蛋白激酶G(PKG)信号通路、磷脂酰肌醇3激酶(PI3K)-蛋白激酶B(AKT)信号通路等。
结论
2
lncRNA PVT1在卵巢癌组织中表达上调,其靶基因富集于细胞组分、分子功能和生物调节等多个生物学过程及TGF-β、cGMP-PKG等肿瘤相关信号通路上,lncRNA PVT1通过调控靶基因的表达在卵巢癌中发挥作用。
Objective
2
To detect the expression of long non-coding RNA plasma-cytoma variant translocation gene 1 (lncRNA PVT1) in ovarian cancer tissues and predict its target gene,and then conduct bioinformatics analysis of the target gene.
Methods
2
The cancer tissues and incisal margin normal tissues of 125 patients with ovarian cancer who underwent surgical treatment in our hospital from June 2019 to December 2019 were collected. The expression of lncRNA PVT1 in cancer tissues and incisal margin normal tissues was detected by RT-PCR. The expression of lncRNA PVT1 in ovarian cancer tissues of patients with different clinicopathological characteristics was compared. The lncRNA PVT1 target genes were screened out by the online tools Anolnc2 database,GEPIA2 database,and UALCAN database to obtain the intersection. DAVID database was used to analyze the GO function and KEGG pathway enrichment of the screened lncRNA PVT1 target gene.
Results
2
Compared with incisal margin normal tissues,the relative expression of lncRNA PVT1 in cancer tissues significantly increased (
P
<
0.05). The relative expression of lncRNA PVT1 in cancer tissues of ovarian patients with TNM stage Ⅲ to Ⅳ,poorly differentiated or undifferentiation were higher than those of ovarian patients with TNM stage Ⅰ to Ⅱ,moderately or well differentiated,respectively (
P
<
0.05). There were 44 target genes of lncRNA
PVT1. GO function analysis found that the target gene functions were mainly enriched in cell cycle regulation,transcription regulation of RNA polymerase Ⅱ promoter,transcription factor activity,lysine oxidase activity,extracellular matrix,cytoplasm,etc. KEGG pathway analysis showed that the pathway it participated in were mainly enriched in cancer-related signal pathway,transforming growth factor-β (TGF-β) signal pathway,extracellular matrix receptor interaction,cyclic guanosine phosphate (cGMP)-protein kinase G (PKG) signal pathway,phosphatidylinositol 3-kinases (PI3K)-RAC-alpha serine/threonine-protein kinase (AKT) signal pathway,etc.
Conclusion
2
The expression of lncRNA PVT1 is up-regulated in ovarian cancer tissues. Its target genes are enriched in multiple biological processes such as cell components,molecular functions,biological regulation and tumor-related signaling pathways such as TGF-β,CGMP-PKG. lncRNA PVT1 plays a role in ovarian cancer by regulating the expression of target genes.
卵巢癌lncRNA PVT1靶基因生物信息学
ovarian cancerlncRNA PVT1target genebioinformatics
Siegel RL,Miller KD,Jemal A.Cancer statistics,2020[J].CA Cancer J Clin,2020,70(1):7-30.doi:10.3322/caac.21590http://dx.doi.org/10.3322/caac.21590.
Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.doi:10.3322/caac.21660http://dx.doi.org/10.3322/caac.21660.
Bruno A,Noonan DM,Valli R,et al.Human RNASET2:a highly pleiotropic and evolutionary conserved tumor suppressor gene involved in the control of ovarian cancer pathogenesis[J].Int J Mol Sci,2022,23(16):9074.doi:10.3390/ijms23169074http://dx.doi.org/10.3390/ijms23169074.
Lin W,Zhou Q,Wang CQ,et al.LncRNAs regulate metabolism in cancer[J].Int J Biol Sci,2020,16(7):1194-1206.doi:10.7150/ijbs.40769http://dx.doi.org/10.7150/ijbs.40769.
Liu K,Xu Q.LncRNA PVT1 regulates gallbladder cancer progression through miR-30d-5p[J].J Biol Regul Homeost Agents,2020,34(3):875-883.doi:10.23812/20-180-A-32http://dx.doi.org/10.23812/20-180-A-32.
Wu Y,Gu W,Han X,et al.LncRNA PVT1 promotes the progression of ovarian cancer by activating TGF-β pathway via miR-148a-3p/AGO1 axis[J].J Cell Mol Med,2021,25(17):8229-8243.doi:10.1111/jcmm.16700http://dx.doi.org/10.1111/jcmm.16700.
Mahima M,Mahmood T,Ved A,et al.An in-depth analysis of ovarian cancer:pathogenesis and clinical manifestation[J].Drug Res (Stuttg),2022,72(8):424-434.doi:10.1055/a-1867-4654http://dx.doi.org/10.1055/a-1867-4654.
Friedrich M,Friedrich D,Kraft C,et al.Multimodal treatment of primary advanced ovarian cancer[J].Anticancer Res,2021,41(7):3253-3260.doi:10.21873/anticanres.15111http://dx.doi.org/10.21873/anticanres.15111.
Chen F,Yang J,Fang M,et al.Necroptosis-related lncRNA to establish novel prognostic signature and predict the immunotherapy response in breast cancer[J].J Clin Lab Anal,2022,36(4):e24302.doi:10.1002/jcla.24302http://dx.doi.org/10.1002/jcla.24302.
Tsang SV,Rainusso N,Liu M,et al.LncRNA PVT-1 promotes osteosarcoma cancer stem-like properties through direct interaction with TRIM28 and TSC2 ubiquitination[J].Oncogene,2022,41(50):5373-5384.doi:10.1038/s41388-022-02538-whttp://dx.doi.org/10.1038/s41388-022-02538-w.
Lin X,Zhuang S,Chen X,et al.lncRNA ITGB8-AS1 functions as a ceRNA to promote colorectal cancer growth and migration through integrin-mediated focal adhesion signaling[J].Mol Ther,2022,30(2):688-702.doi:10.1016/j.ymthe.2021.08.011http://dx.doi.org/10.1016/j.ymthe.2021.08.011.
Qu C,Dai C,Guo Y,et al.Long non-coding RNA PVT1-mediated miR-543/SERPINI1 axis plays a key role in the regulatory mechanism of ovarian cancer[J].Biosci Rep,2020,40(6):BSR20200800.doi:10.1042/BSR20200800http://dx.doi.org/10.1042/BSR20200800.
Dong L,Wang H,Gao Y,et al.Long non-coding RNA PVT1 promotes the proliferation,migration and EMT process of ovarian cancer cells by regulating CTGF[J].Oncol Lett,2022,25(2):71.doi:10.3892/ol.2022.13657http://dx.doi.org/10.3892/ol.2022.13657.
Kumari A,Shonibare Z,Monavarian M,et al.TGFβ signaling networks in ovarian cancer progression and plasticity[J].Clin Exp Metastasis,2021,38(2):139-161.doi:10.1007/s10585-021-10077-zhttp://dx.doi.org/10.1007/s10585-021-10077-z.
Lan T,Li Y,Wang Y,et al.Increased endogenous PKG I activity attenuates EGF-induced proliferation and migration of epithelial ovarian cancer via the MAPK/ERK pathway[J].Cell Death Dis,2023,14(1):39.doi:10.1038/s41419-023-05580-yhttp://dx.doi.org/10.1038/s41419-023-05580-y.
Li H,Prever L,Hirsch E,et al.Targeting PI3K/AKT/mTOR signaling pathway in breast cancer[J].Cancers (Basel),2021,13(14):3517.doi:10.3390/cancers13143517http://dx.doi.org/10.3390/cancers13143517.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621